Phase 3 Stroke Trial, Recruiting NCT06596369 Sponsor: University of Alberta Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06596369
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Spinal cord injury group:

  • Adults between 18 and 75 years old who have had a spinal cord injury at the neck level (between the C3 and C8 vertebrae)
  • People who are at least 1 year past their injury date
  • People taking muscle relaxant or anti-spasm medications must have been on a stable dose for at least 4 weeks before screening

Stroke group:

  • Adults between 18 and 75 years old who have had any type of stroke that affected movement in their arm(s), with some movement still remaining
  • People who are at least 6 months past their stroke
  • People who have had Botox-type injections for muscle stiffness must be at least 4 months past their last injection, or within 2 months of finishing the study (confirm with trial site)
  • People taking muscle relaxant or anti-spasm medications must have been on a stable dose for at least 4 weeks before screening

Who may not be able to join:

  • Women who are pregnant
  • People who have difficulty speaking or understanding language
  • People with severe muscle stiffness, rated 3 or higher on a standard medical scale called the Modified Ashworth Scale
  • People who have an implanted medical device, such as a pacemaker, defibrillator, deep brain stimulator, vagus nerve stimulator, eye implant, or medication pump
  • People who have any conductive, magnetic, or metal implants in their head
  • People with a personal history of seizures or epilepsy
  • People taking any medication that is known to lower the threshold for seizures

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jessica D'Amico, PhD, University of Alberta

Phone: 7807357917

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
15 June 2024
Est. completion
14 September 2029

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Spinal Excitability; Corticospinal excitability; Clinical assessment of UE function; Changes in Intracortical Excitability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov